Amidst the urgency to develop the coronavirus vaccine at the earliest, different countries are now claiming to be in different phases of trials of the vaccine. Here's all you need to know about the development of the vaccine around the world.
Vaccine in India:
COVAXIN has entered the human trials phase. Jointly developed by Bharat Biotech, Indian Council of Medical Research (ICMR), and National Institute of Virology, Pune.
AIIMS-Patna has started testing the candidate vaccine on 10 volunteers picked by the hospital authority for the trial, reported AIR.
According to the report, the first dose of the vaccine has been administered to the study participants, who will be given the second dose after an interval of 14 days.
Vaccine in USA:
Biotech firm Moderna Inc's experimental vaccine for COVID-19 showed it was safe and provoked immune responses in all 45 healthy volunteers in an ongoing early-stage study, U.S. researchers reported on Tuesday.
Volunteers who got two doses of the vaccine had high levels of virus-killing antibodies that exceeded the average levels seen in people who had recovered from COVID-19, the team reported in the New England Journal of Medicine.
The US will deliver a Coronavirus COVID19 vaccine in the “record-breaking time”, said American President Donald Trump.
The US President has said that America will deliver a COVID19 vaccine in record-breaking time through “Operation Warp Speed”.
Vaccine in Russia:
Russian scientists said they are eyeing to launch the vaccine by mid-August, says a report.
According to Director of the Gamaleya Scientific Research Institute, Alexander Gintsburg, there are hopes that "a small amount" of the vaccine would be available to people in the middle of August, and private companies would start producing vaccines in the beginning or the middle of September, as reported by Sputnik News.
The head of the research institute added that the vaccine would not be available in pharmacies in the near future.
Vaccine in China:
CanSino Biologics seems to be one of the front runners in the race to develop a vaccine for the novel coronavirus.
The vaccine candidate of the Chinese drugmaker has been approved for limited usage for the military in China for a period of one year.
Its vaccine candidate Ad5-nCoV is developed using the drugmaker's adenovirus-based viral vector vaccine technology platform.
Coronavirus vaccine UK, Oxford, AstraZeneca
In the UK, two potential Coronavirus vaccine candidates have raised hopes. One is developed by the University of Oxford and AstraZeneca is at Phase III. Another is being developed by Imperial College London and its has entered the Phase II stage.
Content created and supplied by: Faithy_Media (via Opera News )